WO2005046732A3 - Methodes et compositions d'inhibition de la replication du vih-1 - Google Patents

Methodes et compositions d'inhibition de la replication du vih-1 Download PDF

Info

Publication number
WO2005046732A3
WO2005046732A3 PCT/US2004/036492 US2004036492W WO2005046732A3 WO 2005046732 A3 WO2005046732 A3 WO 2005046732A3 US 2004036492 W US2004036492 W US 2004036492W WO 2005046732 A3 WO2005046732 A3 WO 2005046732A3
Authority
WO
WIPO (PCT)
Prior art keywords
replication
hiv
compositions
methods
inhibition
Prior art date
Application number
PCT/US2004/036492
Other languages
English (en)
Other versions
WO2005046732A2 (fr
Inventor
Sharon M Wahl
Nancy Vazquez-Maldonado
Teresa Greenwell-Wild
Original Assignee
Us Health
Sharon M Wahl
Nancy Vazquez-Maldonado
Teresa Greenwell-Wild
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Sharon M Wahl, Nancy Vazquez-Maldonado, Teresa Greenwell-Wild filed Critical Us Health
Priority to US10/578,536 priority Critical patent/US8288439B2/en
Publication of WO2005046732A2 publication Critical patent/WO2005046732A2/fr
Publication of WO2005046732A3 publication Critical patent/WO2005046732A3/fr
Priority to US13/650,526 priority patent/US20130116305A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes et des compositions de réduction de la réplication du VIH-1 dans les cellules humaines, et en particulier dans les macrophages humains. L'invention concerne, en particulier, l'utilisation d'inhibiteurs de l'expression de P21 (CDKN1A) pour atténuer une telle réplication. L'invention concerne également l'utilisation d'oligonucléotides P21 anti-sens, de siARN et/ou de 2-cyano-3, 12-dioxooléana-1,9-diène-28-oique (CDDO) pour atténuer une telle réplication.
PCT/US2004/036492 2003-11-04 2004-11-03 Methodes et compositions d'inhibition de la replication du vih-1 WO2005046732A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/578,536 US8288439B2 (en) 2003-11-04 2004-11-03 Methods and compositions for the inhibition of HIV-1 replication
US13/650,526 US20130116305A1 (en) 2003-11-04 2012-10-12 Methods and compositions for the inhibition of hiv-1 replication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51673403P 2003-11-04 2003-11-04
US60/516,734 2003-11-04

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/650,526 Division US20130116305A1 (en) 2003-11-04 2012-10-12 Methods and compositions for the inhibition of hiv-1 replication

Publications (2)

Publication Number Publication Date
WO2005046732A2 WO2005046732A2 (fr) 2005-05-26
WO2005046732A3 true WO2005046732A3 (fr) 2005-09-29

Family

ID=34590128

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036492 WO2005046732A2 (fr) 2003-11-04 2004-11-03 Methodes et compositions d'inhibition de la replication du vih-1

Country Status (2)

Country Link
US (2) US8288439B2 (fr)
WO (1) WO2005046732A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US8993640B2 (en) 2012-04-27 2015-03-31 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US9000188B2 (en) 2008-07-22 2015-04-07 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9174941B2 (en) 2010-12-17 2015-11-03 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9290536B2 (en) 2011-03-11 2016-03-22 Reata Pharmaceuticals, Inc. C4 monomethyl triterpenoid derivatives and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9593074B2 (en) 2012-09-10 2017-03-14 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
US7176237B2 (en) 2002-01-15 2007-02-13 The Trustees Of Dartmouth College Tricyclic-bis-enone derivatives and methods of use thereof
JP4576945B2 (ja) * 2004-02-09 2010-11-10 ソニー株式会社 物質間の相互作用を検出する検出表面と該検出表面を用いるセンサチップとセンサ装置及び検出方法
US8921340B2 (en) 2006-11-17 2014-12-30 Trustees Of Dartmouth College Methods for using synthetic triterpenoids in the treatment of bone or cartilage diseases or conditions
WO2008064132A2 (fr) 2006-11-17 2008-05-29 Trustees Of Dartmouth College Triterpénoïdes synthétiques et bis-énones tricycliques pour une utilisation dans la stimulation de croissance osseuse et cartilagineuse
US7714012B2 (en) 2006-11-17 2010-05-11 Trustees Of Dartmouth University Synthesis and biological activities of new tricyclic-bis-enones (TBEs)
WO2009089545A1 (fr) 2008-01-11 2009-07-16 Reata Pharmaceuticals, Inc. Triterpénoïdes synthétiques et procédés d'utilisation dans le traitement de maladies
US8071632B2 (en) 2008-04-18 2011-12-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: novel derivatives of oleanolic acid
US20120087949A1 (en) * 2008-12-19 2012-04-12 University Of Florida Research Foundation, Inc. Oligonucleotide micelles
WO2011049603A1 (fr) * 2009-10-22 2011-04-28 Dana-Farber Cancer Institute, Inc. Biomarqueurs permettant d'identifier des sous-ensembles de cellules t spécifiques du vih
SI2558105T1 (sl) 2010-04-12 2020-02-28 Reata Pharmaceuticals, Inc. Bardoksolon metil za zdravljenje debelosti
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2016033132A1 (fr) 2014-08-26 2016-03-03 Trustees Of Dartmouth College Analogues pyridyles du 1-(2-cyano-3,12-dioxooléana-1,9(11)dièn-28-oyl)imidazole
US10189791B2 (en) 2014-08-26 2019-01-29 Trustees Of Dartmouth College Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazole
WO2016070063A1 (fr) * 2014-10-31 2016-05-06 The Regents Of The University Of California Compositions et méthodes de traitement d'un dysfonctionnement cognitif associé au vih
ES2865163T3 (es) 2015-09-23 2021-10-15 Reata Pharmaceuticals Inc Derivados de ácido oleanólico modificado en C4 para la inhibición de il-17 y otros usos
NZ753546A (en) 2016-11-08 2022-10-28 Reata Pharmaceuticals Holdings Llc Methods of treating alport syndrome using bardoxolone methyl or analogs thereof
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088191A1 (fr) * 2000-03-29 2001-11-22 The United States Of America As Represented By The Department Of Veterans Affairs Un nouvel inhibiteur specifique de l'inhibiteur p21waf1cip1

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6869925B1 (en) * 1992-09-09 2005-03-22 Amgen Inc. Inhibition of retrovirus infection
EP0666755B1 (fr) 1992-09-09 2003-04-23 Amgen Inc. Inhibition de l'infection par l'hiv
WO1994017097A1 (fr) 1993-01-19 1994-08-04 Regents Of The University Of Minnesota Fragments de fibronectine synthetique utilises comme inhibiteurs d'infections retrovirales
US5916919A (en) * 1997-06-27 1999-06-29 Dalhousie University Retrovirus protease inhibitors
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
WO2004016753A2 (fr) * 2002-08-15 2004-02-26 Human Genome Sciences, Inc. Anticorps se fixant de facon immunospecifique a des recepteurs trail

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088191A1 (fr) * 2000-03-29 2001-11-22 The United States Of America As Represented By The Department Of Veterans Affairs Un nouvel inhibiteur specifique de l'inhibiteur p21waf1cip1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GARTEL ANDREI L ET AL: "The role of the cyclin-dependent kinase inhibitor p21 in apoptosis", MOLECULAR CANCER THERAPEUTICS, vol. 1, no. 8, June 2002 (2002-06-01), pages 639 - 649, XP002325181, ISSN: 1535-7163 *
GOMEZ ET AL.: "Cytoplasmic p21 WAF1/Cip1 protects U937 promonocytic cells from HIV mediated apoptosis", 24 May 2002 (2002-05-24), XP002324902, Retrieved from the Internet <URL:WWW.RETROCONFERENCE.ORG/2002/POSTERS/13446.PDF> [retrieved on 20050413] *
KAWATA SANAE ET AL: "p21Waf1/Cip1/Sdi1 prevents apoptosis as well as stimulates growth in cells transformed or immortalized by human T-cell leukemia virus type 1-encoded Tax.", JOURNAL OF VIROLOGY, vol. 77, no. 13, July 2003 (2003-07-01), pages 7291 - 7299, XP002324904, ISSN: 0022-538X *
POLUHA WOJCIECH ET AL: "The cyclin-dependent kinase inhibitor p21-WAF1 is required for survival of differentiating neuroblastoma cells", MOLECULAR AND CELLULAR BIOLOGY, vol. 16, no. 4, 1996, pages 1335 - 1341, XP002325238, ISSN: 0270-7306 *
TIAN HUI ET AL: "p21WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis", CANCER RESEARCH, vol. 60, no. 3, 1 February 2000 (2000-02-01), pages 679 - 684, XP002325239, ISSN: 0008-5472 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE45288E1 (en) 2008-04-18 2014-12-09 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
USRE45325E1 (en) 2008-04-18 2015-01-06 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring
US9102681B2 (en) 2008-04-18 2015-08-11 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17
US9233998B2 (en) 2008-04-18 2016-01-12 Reata Pharmaceuticals, Inc. Natural product analogs including an anti-inflammatory cyanoenone pharmacore and methods of use
US9249089B2 (en) 2008-04-18 2016-02-02 Reata Pharmaceuticals, Inc. Antioxidant inflammation modulators: C-17 homologated oleanolic acid derivatives
US9000188B2 (en) 2008-07-22 2015-04-07 Trustees Of Dartmouth College Monocyclic cyanoenones and methods of use thereof
US9174941B2 (en) 2010-12-17 2015-11-03 Reata Pharmaceuticals, Inc. Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
US9290536B2 (en) 2011-03-11 2016-03-22 Reata Pharmaceuticals, Inc. C4 monomethyl triterpenoid derivatives and methods of use thereof
US8993640B2 (en) 2012-04-27 2015-03-31 Reata Pharmaceuticals, Inc. 2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9593074B2 (en) 2012-09-10 2017-03-14 Reata Pharmaceuticals, Inc. C17-alkanediyl and alkenediyl derivatives of oleanolic acid and methods of use thereof

Also Published As

Publication number Publication date
WO2005046732A2 (fr) 2005-05-26
US20130116305A1 (en) 2013-05-09
US8288439B2 (en) 2012-10-16
US20080242602A1 (en) 2008-10-02

Similar Documents

Publication Publication Date Title
WO2005046732A3 (fr) Methodes et compositions d&#39;inhibition de la replication du vih-1
WO2003070283A3 (fr) Agent inhibant l&#39;evolution ou la progression des maladies proliferatives, en particulier des cancers, et composition pharmaceutique contenant ledit agent
WO2007026251A3 (fr) Utilisation d&#39;inhibiteurs combines c-kit/fgfr3 pour le traitement du myelome multiple
EP2426203A3 (fr) Agents utiles pour le traitement de la dystrophie musculaire facio-scapulo-humérale
WO2008064916A3 (fr) Moyen de traitement de fuites vasculaires
TW200501893A (en) Method of inhibiting water content variation of composition and use thereof
WO2006031901A3 (fr) Petits arn interferents inhibant efficacement l&#39;expression genique virale et methodes d&#39;utilisation associees
WO2009118662A3 (fr) Compositions et méthodes de traitement de la perte osseuse
WO2011008730A3 (fr) Modification chimique de petits arn en épingle à cheveux pour l&#39;inhibition d&#39;une expression de gène
WO2005047477A3 (fr) Arn a elements repetitifs intercales utilises comme substrat, inhibiteurs et vehicules d&#39;apport pour l&#39;interference d&#39;arn
EP1691842A4 (fr) Traitement de maladies proliferatives au moyen d&#39;un oligomere antisens iap et agent chimiotherapeutique
WO2008152131A3 (fr) Inhibition par arni de l&#39;expression du canal alpha-enac
WO2005117557A3 (fr) Systeme d&#39;expression
EP2251039A3 (fr) Oligo-ARN double brin inhibant l&#39;expression de bcl-2 et composition pharmaceutique le contenant
WO2007084237A3 (fr) Nouveaux agonistes synthétiques de récepteurs &#39;toll-like&#39; contenant des modifications cg de dinucléotide
WO2003103662A3 (fr) Inhibiteurs de la glycoproteine vi
WO2005049832A3 (fr) Interference d&#39;acides nucleiques specifiques a fcgriia
WO2009066967A3 (fr) Acides nucléiques peptidiques (anp) antisens à microarn, compositions les comprenant, et procédés pour les utiliser et les évaluer
WO2007032794A3 (fr) Inhibition de l&#39;expression genique virale a l&#39;aide d&#39;un petit arn interferent
WO2007106915A3 (fr) Anticorps à efgl 7 et leurs procédés d&#39;utilisation
WO2009009034A3 (fr) Procédées et compositions utiles dans le traitement de la mucosite
WO2006015258A3 (fr) Procedes et compositions associes aux proteines argonautes
WO2004022782A3 (fr) Compositions et methodes d&#39;inhibition a specificite ou declenchement tissulaire de l&#39;expression de genes
WO2009044158A3 (fr) Inhibiteurs et utilisations
WO2004093856A3 (fr) Combinaison d&#39;un inhibiteur de cox-2 et d&#39;un agent antineoplastique de type d&#39;alkylation destinee au traitement de la neoplasie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
WWE Wipo information: entry into national phase

Ref document number: 10578536

Country of ref document: US